AU2001265119A1 - Naaladase inhibitors for treating amyotrophic lateral sclerosis - Google Patents
Naaladase inhibitors for treating amyotrophic lateral sclerosisInfo
- Publication number
- AU2001265119A1 AU2001265119A1 AU2001265119A AU6511901A AU2001265119A1 AU 2001265119 A1 AU2001265119 A1 AU 2001265119A1 AU 2001265119 A AU2001265119 A AU 2001265119A AU 6511901 A AU6511901 A AU 6511901A AU 2001265119 A1 AU2001265119 A1 AU 2001265119A1
- Authority
- AU
- Australia
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- treating amyotrophic
- naaladase inhibitors
- naaladase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20731900P | 2000-05-30 | 2000-05-30 | |
US60/207,319 | 2000-05-30 | ||
PCT/US2001/017325 WO2001091738A2 (en) | 2000-05-30 | 2001-05-30 | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001265119A1 true AU2001265119A1 (en) | 2001-12-11 |
Family
ID=22770034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001265119A Abandoned AU2001265119A1 (en) | 2000-05-30 | 2001-05-30 | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
Country Status (3)
Country | Link |
---|---|
US (1) | US20020013295A1 (en) |
AU (1) | AU2001265119A1 (en) |
WO (1) | WO2001091738A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
CA2212846A1 (en) | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
JP4234430B2 (en) | 2001-01-17 | 2009-03-04 | エムジーアイ ジーピー インコーポレイティッド | NAALADase inhibitors containing thiols |
JP4625236B2 (en) * | 2001-05-11 | 2011-02-02 | エーザイ インコーポレーテッド | Hydroxamic acid and acylhydroxamine as NAALADase inhibitors |
ATE419232T1 (en) | 2001-05-30 | 2009-01-15 | Guilford Pharm Inc | THIOLALKYLBEZOIC ACID DERIVATIVES |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
AU2002356844C1 (en) * | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
GB2390539A (en) * | 2002-07-08 | 2004-01-14 | Pantherix Ltd | Tri-substituted benzene & pyridine derivatives with 2 or 3 carboxy-comprising substituents for use as antibiotic or antibacterial agents |
ATE433445T1 (en) * | 2003-03-03 | 2009-06-15 | Eisai Corp North America | THIOLACTONE AS NAALADASE INHIBITORS |
EP2338892A1 (en) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
CN107820425B (en) * | 2015-06-15 | 2021-08-31 | Nmd制药股份公司 | Compounds for the treatment of neuromuscular disorders |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
TR199901173T2 (en) * | 1996-09-27 | 1999-07-21 | Guilford Pharmaceuticals, Inc. | Methods and compositions of NAALADase for the treatment of glutamate abnormality and regulation of neuronal activity in vivo. |
US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
ATE305449T1 (en) * | 1998-07-06 | 2005-10-15 | Guilford Pharm Inc | NAALADASE INHIBITORS APPLICABLE AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
-
2001
- 2001-05-30 WO PCT/US2001/017325 patent/WO2001091738A2/en active Application Filing
- 2001-05-30 AU AU2001265119A patent/AU2001265119A1/en not_active Abandoned
- 2001-05-30 US US09/866,729 patent/US20020013295A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001091738A2 (en) | 2001-12-06 |
WO2001091738A3 (en) | 2002-09-06 |
US20020013295A1 (en) | 2002-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001265119A1 (en) | Naaladase inhibitors for treating amyotrophic lateral sclerosis | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2001238369A1 (en) | Method for treating thyroid disorders | |
GB9912961D0 (en) | Metalloprotease inhibitors | |
AUPQ859000A0 (en) | Apparatus for surface engineering | |
AU2002219555A1 (en) | VLA-4 Inhibitors | |
AU4882101A (en) | Mmp-12 inhibitors | |
AU2001258784A1 (en) | Tyrosine phosphatase inhibitors | |
AU2002211663A1 (en) | Nf-$g(k)b inhibitors | |
AU2001234088A1 (en) | TNF-alpha inhibitors | |
MXPA03006467A (en) | Thiol-based naaladase inhibitors. | |
PL350452A1 (en) | Dihetero-substituted metalloprotease inhibitors | |
AU2001236052A1 (en) | Urease inhibitors | |
AU1597201A (en) | Pyrrolecarbonylimino derivatives as naaladase inhibitors | |
AU4433700A (en) | Prolyl endopeptidase inhibitor | |
AU2002211662A1 (en) | Nf-kappab inhibitors | |
AU2001234730A1 (en) | Method for inhibiting complement activation | |
AUPR152100A0 (en) | Method for treating coral | |
AU2001259218A1 (en) | Substituted phenyl farnesyltransferase inhibitors | |
EG24462A (en) | Compounds for treating fundic disaccomodation | |
AU2608301A (en) | Methods for inhibiting mastocytosis | |
AU2002211563A1 (en) | Compounds useful for treating hypertriglyceridemia | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
AU2001220281A1 (en) | Rollerboard for road-skiing | |
AU2001265425A1 (en) | Compositions for treating biofilm |